stella
beta
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis — Stella
Recruiting
Back to Minimal Change Disease (MCD) trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Peking University First Hospital, Beijing, Beijing Municipality
View full record on ClinicalTrials.gov